239 related articles for article (PubMed ID: 31907197)
1. Induction of Effective Immunity against Trypanosoma cruzi.
Williams T; Guerrero-Ros I; Ma Y; Matos Dos Santos F; Scherer PE; Gordillo R; Horta A; Macian F; Weiss LM; Huang H
Infect Immun; 2020 Mar; 88(4):. PubMed ID: 31907197
[TBL] [Abstract][Full Text] [Related]
2. Inducible suicide vector systems for Trypanosoma cruzi.
Ma Y; Weiss LM; Huang H
Microbes Infect; 2015 Jun; 17(6):440-50. PubMed ID: 25899945
[TBL] [Abstract][Full Text] [Related]
3. Memory-like NK Cells Are a Critical Component of Vaccine-Induced Immunity to Trypanosoma cruzi Infection.
Horta AL; Gigley J; Boutet M; Lavau G; Weiss LM; Huang H
J Immunol; 2024 Feb; 212(4):617-631. PubMed ID: 38197653
[TBL] [Abstract][Full Text] [Related]
4. Trypanosoma cruzi 80 kDa prolyl oligopeptidase (Tc80) as a novel immunogen for Chagas disease vaccine.
Bivona AE; Sánchez Alberti A; Matos MN; Cerny N; Cardoso AC; Morales C; González G; Cazorla SI; Malchiodi EL
PLoS Negl Trop Dis; 2018 Mar; 12(3):e0006384. PubMed ID: 29601585
[TBL] [Abstract][Full Text] [Related]
5. Critical contribution of immunoproteasomes in the induction of protective immunity against Trypanosoma cruzi in mice vaccinated with a plasmid encoding a CTL epitope fused to green fluorescence protein.
Chou B; Hisaeda H; Shen J; Duan X; Imai T; Tu L; Murata S; Tanaka K; Himeno K
Microbes Infect; 2008 Mar; 10(3):241-50. PubMed ID: 18321749
[TBL] [Abstract][Full Text] [Related]
6. Cruzipain and Its Physiological Inhibitor, Chagasin, as a DNA-Based Therapeutic Vaccine Against
Cerny N; Bivona AE; Sanchez Alberti A; Trinitario SN; Morales C; Cardoso Landaburu A; Cazorla SI; Malchiodi EL
Front Immunol; 2020; 11():565142. PubMed ID: 33162979
[TBL] [Abstract][Full Text] [Related]
7. Experimental Nanovaccine Offers Protection Against Repeat Exposures to
Chowdhury IH; Lokugamage N; Garg NJ
Front Immunol; 2020; 11():595039. PubMed ID: 33414785
[TBL] [Abstract][Full Text] [Related]
8. Experimental Chagas disease in Balb/c mice previously vaccinated with T. rangeli. II. The innate immune response shows immunological memory: reality or fiction?
Basso B; Marini V
Immunobiology; 2015 Mar; 220(3):428-36. PubMed ID: 25454810
[TBL] [Abstract][Full Text] [Related]
9. Cruzipain induces both mucosal and systemic protection against Trypanosoma cruzi in mice.
Schnapp AR; Eickhoff CS; Sizemore D; Curtiss R; Hoft DF
Infect Immun; 2002 Sep; 70(9):5065-74. PubMed ID: 12183554
[TBL] [Abstract][Full Text] [Related]
10. Efficient protective immunity against Trypanosoma cruzi infection after nasal vaccination with recombinant Sendai virus vector expressing amastigote surface protein-2.
Duan X; Yonemitsu Y; Chou B; Yoshida K; Tanaka S; Hasegawa M; Tetsutani K; Ishida H; Himeno K; Hisaeda H
Vaccine; 2009 Oct; 27(44):6154-9. PubMed ID: 19712768
[TBL] [Abstract][Full Text] [Related]
11.
Gupta S; Salgado-Jiménez B; Lokugamage N; Vázquez-Chagoyán JC; Garg NJ
Front Immunol; 2019; 10():1456. PubMed ID: 31293599
[No Abstract] [Full Text] [Related]
12. Perforin and gamma interferon expression are required for CD4+ and CD8+ T-cell-dependent protective immunity against a human parasite, Trypanosoma cruzi, elicited by heterologous plasmid DNA prime-recombinant adenovirus 5 boost vaccination.
de Alencar BC; Persechini PM; Haolla FA; de Oliveira G; Silverio JC; Lannes-Vieira J; Machado AV; Gazzinelli RT; Bruna-Romero O; Rodrigues MM
Infect Immun; 2009 Oct; 77(10):4383-95. PubMed ID: 19651871
[TBL] [Abstract][Full Text] [Related]
13. Effects of IFN-γ coding plasmid supplementation in the immune response and protection elicited by Trypanosoma cruzi attenuated parasites.
Pérez Brandán C; Mesías AC; Parodi C; Cimino RO; Pérez Brandán C; Diosque P; Basombrío MÁ
BMC Infect Dis; 2017 Nov; 17(1):732. PubMed ID: 29178839
[TBL] [Abstract][Full Text] [Related]
14. Oral exposure to Trypanosoma cruzi elicits a systemic CD8⁺ T cell response and protection against heterotopic challenge.
Collins MH; Craft JM; Bustamante JM; Tarleton RL
Infect Immun; 2011 Aug; 79(8):3397-406. PubMed ID: 21628516
[TBL] [Abstract][Full Text] [Related]
15. Delivery of antigenic candidates by a DNA/MVA heterologous approach elicits effector CD8(+)T cell mediated immunity against Trypanosoma cruzi.
Gupta S; Garg NJ
Vaccine; 2012 Nov; 30(50):7179-86. PubMed ID: 23079191
[TBL] [Abstract][Full Text] [Related]
16. TcVac1 vaccine delivery by intradermal electroporation enhances vaccine induced immune protection against Trypanosoma cruzi infection in mice.
Hegazy-Hassan W; Zepeda-Escobar JA; Ochoa-García L; Contreras-Ortíz JME; Tenorio-Borroto E; Barbabosa-Pliego A; Aparicio-Burgos JE; Oros-Pantoja R; Rivas-Santiago B; Díaz-Albiter H; Garg NJ; Vázquez-Chagoyán JC
Vaccine; 2019 Jan; 37(2):248-257. PubMed ID: 30497833
[TBL] [Abstract][Full Text] [Related]
17. Type 1 immunity provides optimal protection against both mucosal and systemic Trypanosoma cruzi challenges.
Hoft DF; Eickhoff CS
Infect Immun; 2002 Dec; 70(12):6715-25. PubMed ID: 12438346
[TBL] [Abstract][Full Text] [Related]
18. Knockout of the dhfr-ts gene in Trypanosoma cruzi generates attenuated parasites able to confer protection against a virulent challenge.
Perez Brandan C; Padilla AM; Xu D; Tarleton RL; Basombrio MA
PLoS Negl Trop Dis; 2011 Dec; 5(12):e1418. PubMed ID: 22180798
[TBL] [Abstract][Full Text] [Related]
19. Therapeutical effects of vaccine from Trypanosoma cruzi amastigote surface protein 2 by simultaneous inoculation with live parasites.
Ribeiro FAP; Pontes C; Machado AMV; Bruna-Romero O; Quintana HT; De Oliveira F; De Vasconcelos JRC; Ribeiro DA
J Cell Biochem; 2019 Mar; 120(3):3373-3383. PubMed ID: 30246366
[TBL] [Abstract][Full Text] [Related]
20. Previously unrecognized vaccine candidates control Trypanosoma cruzi infection and immunopathology in mice.
Bhatia V; Garg NJ
Clin Vaccine Immunol; 2008 Aug; 15(8):1158-64. PubMed ID: 18550728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
